



Medicines & Healthcare products  
Regulatory Agency



**MHRA**

10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom

[gov.uk/mhra](https://gov.uk/mhra)

Ms Heather House  
UNIVERSITY OF OXFORD  
CLINICAL TRIALS AND RESEARCH GOVERNANCE, JOINT RESEARCH OFFICE,  
1ST FLOOR, BOUNDARY BROOK HOUSE, CHURCHILL DRIVE, HEADINGTON  
OXFORD  
OX3 7LQ  
UNITED KINGDOM

25/06/2020

Dear Ms Heather House,

**THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 S.I. 2004/1031**

Our Reference:	CTA 21584/0423/001-0007
Eudract Number:	2020-001113-21
Product:	Lopinavir/ritonavir, Dexamethasone, Hydroxychloroquine, Azithromycin
Protocol number:	NDPHRECOVERY
Substantial Amendment Code Number:	Substantial Amendment 6, 18 June 2020

**NOTICE OF ACCEPTANCE OF AMENDMENT**

I am writing to inform you that the Licensing Authority accepts the proposed amendment to your clinical trial authorisation (CTA), received on 23/06/2020.

This amendment may therefore be made.

You are reminded that where it is appropriate, the Ethics Committee should also be notified of amendments.

Yours sincerely,

**Clinical Trials Unit  
MHRA**